Marker of proliferation Ki-67 expression is associated with transforming growth factor beta 1 and can predict the prognosis of patients with hepatic B virus-related hepatocellular carcinoma

Chengkun Yang; Hao Su; Xiwen Liao; Chuangye Han; Tingdong Yu; Guangzhi Zhu; Xiangkun Wang; Cheryl Ann Winkler; Stephen J. O’Brien; Tao Peng; Stephen James O'Brien

doi:10.2147/cmar.s162595

Marker of proliferation Ki-67 expression is associated with transforming growth factor beta 1 and can predict the prognosis of patients with hepatic B virus-related hepatocellular carcinoma

Chengkun Yang
, Hao Su
, Xiwen Liao
, Chuangye Han
, Tingdong Yu
, Guangzhi Zhu
, Xiangkun Wang
, Cheryl Ann Winkler
, Stephen J. O’Brien
, Tao Peng
, Stephen James O'Brien

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

Hepatocellular carcinoma (HCC) is the most frequent malignancy of the liver. Transforming growth factor beta 1 (TGFB1) and marker of proliferation Ki-67 (MKI67) regulate cell proliferation, differentiation, and growth. The association between MKI67 and TGFB1 expression and its clinical implications in HCC remain unknown. Methods: Public databases were used to analyze TGFB1 and MKI67 expression in different pathologic grades/stages and tissue types of HCC. The association between MKI67 and TGFB1 expression was explored using pathway analysis and in a HepG2 cell line treated with TGFB1. Survival analysis was performed to evaluate the prognostic value of TGFB1 and MKI67 expression in patients with hepatitis B virus (HBV)-related HCC. Results: We identified that MKI67 expression was upregulated in liver cancer tissues. MKI67 and TGFB1 expression levels were different in various stages and tissue types of liver cancer. Furthermore, MKI67 expression was associated with TGFB1 expression in liver cancer tissues and HepG2 cells. Patients with HBV-related HCC and a higher level of MKI67 expression had a worse prognosis. Moreover, a nomogram was conducted to predict the clinical outcomes of patients with HBV-related HCC. Conclusion: MKI67 expression level was associated with TGFB1 expression in liver cancer tissues and a HepG2 cell line. MKI67 expression level can predict the clinical outcomes of patients with HBV-related HCC.

Original language	American English
Pages (from-to)	679-696
Number of pages	18
Journal	Cancer Management and Research
Volume	10
DOIs	https://doi.org/10.2147/cmar.s162595
State	Published - Apr 10 2018

Bibliographical note

Publisher Copyright:
© 2018 Yang et al.

Funding

This work was supported in part by the National Nature Science Foundation of China (Nos.: 81560535, 81072321, 30760243, 30460143, and 30560133), 2009 Program for New Century Excellent Talents in University (NCET), Guangxi Nature Sciences Foundation (No.: GuiKe Gong 1104003A-7), and Guangxi Health Ministry Medicine Grant (Key-Scientific Research-Grant Z201018). We would also like to acknowledge the support by the National Key Clinical Specialty Programs (General Surgery and Oncology) and the Key Laboratory of Early Prevention and Treatment for Regional High-Incidence-Tumor (Guangxi Medical University), Ministry of Education, China. This project has been funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN26120080001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, and the mention of trade names, commercial products, or organizations does not imply endorsement by the US Government. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. This work was supported in part by the National Nature Science Foundation of China (Nos.: 81560535, 81072321, 30760243, 30460143, and 30560133), 2009 Program for New Century Excellent Talents in University (NCET), Guangxi Nature Sciences Foundation (No.: GuiKe Gong 1104003A-7), and Guangxi Health Ministry Medicine Grant (Key-Scientific Research-Grant Z201018). We would also like to acknowledge the support by the National Key Clinical Specialty Programs (General Surgery and Oncology) and the Key Laboratory of Early Prevention and Treatment for Regional High-Incidence-Tumor (Guangxi Medical University), Ministry of Education, China. This project has been funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN26120080001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, and the mention of trade names, commercial products, or organizations does not imply endorsement by the US Government. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

Funders	Funder number
Guangxi Health Ministry Medicine	Z201018
Key Laboratory of Early Prevention and Treatment for Regional High-Incidence-Tumor
National Key Clinical Specialty Programs
National Institutes of Health	HHSN26120080001E
National Cancer Institute
National Natural Science Foundation of China	81560535, 30560133, 81072321, 30760243, 30460143
Ministry of Education of the People's Republic of China
Program for New Century Excellent Talents in University
Natural Science Foundation of Guangxi Province	GuiKe Gong 1104003A-7
Guangxi Traditional Chinese Medical University
Guangxi Medical University

ASJC Scopus Subject Areas

Oncology

Keywords

HBV-related HCC
MKI67
Nomogram
TGFB1

Disciplines

Genetics and Genomics
Life Sciences

Access to Document

10.2147/cmar.s162595

CMARFinal published version, 89.1 KBLicense: Unspecified

Cite this

Yang, C., Su, H., Liao, X., Han, C., Yu, T., Zhu, G., Wang, X., Winkler, C. A., O’Brien, S. J., Peng, T., & O'Brien, S. J. (2018). Marker of proliferation Ki-67 expression is associated with transforming growth factor beta 1 and can predict the prognosis of patients with hepatic B virus-related hepatocellular carcinoma. Cancer Management and Research, 10, 679-696. https://doi.org/10.2147/cmar.s162595

Marker of proliferation Ki-67 expression is associated with transforming growth factor beta 1 and can predict the prognosis of patients with hepatic B virus-related hepatocellular carcinoma. / Yang, Chengkun; Su, Hao; Liao, Xiwen et al.
In: Cancer Management and Research, Vol. 10, 10.04.2018, p. 679-696.

Research output: Contribution to journal › Article › peer-review

Yang, C, Su, H, Liao, X, Han, C, Yu, T, Zhu, G, Wang, X, Winkler, CA, O’Brien, SJ, Peng, T & O'Brien, SJ 2018, 'Marker of proliferation Ki-67 expression is associated with transforming growth factor beta 1 and can predict the prognosis of patients with hepatic B virus-related hepatocellular carcinoma', Cancer Management and Research, vol. 10, pp. 679-696. https://doi.org/10.2147/cmar.s162595

@article{b9b94a0c7b0e4bd189baf998114f98e6,

title = "Marker of proliferation Ki-67 expression is associated with transforming growth factor beta 1 and can predict the prognosis of patients with hepatic B virus-related hepatocellular carcinoma",

abstract = " Hepatocellular carcinoma (HCC) is the most frequent malignancy of the liver. Transforming growth factor beta 1 (TGFB1) and marker of proliferation Ki-67 (MKI67) regulate cell proliferation, differentiation, and growth. The association between MKI67 and TGFB1 expression and its clinical implications in HCC remain unknown. Methods: Public databases were used to analyze TGFB1 and MKI67 expression in different pathologic grades/stages and tissue types of HCC. The association between MKI67 and TGFB1 expression was explored using pathway analysis and in a HepG2 cell line treated with TGFB1. Survival analysis was performed to evaluate the prognostic value of TGFB1 and MKI67 expression in patients with hepatitis B virus (HBV)-related HCC. Results: We identified that MKI67 expression was upregulated in liver cancer tissues. MKI67 and TGFB1 expression levels were different in various stages and tissue types of liver cancer. Furthermore, MKI67 expression was associated with TGFB1 expression in liver cancer tissues and HepG2 cells. Patients with HBV-related HCC and a higher level of MKI67 expression had a worse prognosis. Moreover, a nomogram was conducted to predict the clinical outcomes of patients with HBV-related HCC. Conclusion: MKI67 expression level was associated with TGFB1 expression in liver cancer tissues and a HepG2 cell line. MKI67 expression level can predict the clinical outcomes of patients with HBV-related HCC.",

keywords = "HBV-related HCC, MKI67, Nomogram, TGFB1",

author = "Chengkun Yang and Hao Su and Xiwen Liao and Chuangye Han and Tingdong Yu and Guangzhi Zhu and Xiangkun Wang and Winkler, \{Cheryl Ann\} and O{\textquoteright}Brien, \{Stephen J.\} and Tao Peng and O'Brien, \{Stephen James\}",

note = "Publisher Copyright: {\textcopyright} 2018 Yang et al.",

year = "2018",

month = apr,

day = "10",

doi = "10.2147/cmar.s162595",

language = "American English",

volume = "10",

pages = "679--696",

journal = "Cancer Management and Research",

issn = "1179-1322",

publisher = "Dove Medical Press Ltd",

}

TY - JOUR

T1 - Marker of proliferation Ki-67 expression is associated with transforming growth factor beta 1 and can predict the prognosis of patients with hepatic B virus-related hepatocellular carcinoma

AU - Yang, Chengkun

AU - Su, Hao

AU - Liao, Xiwen

AU - Han, Chuangye

AU - Yu, Tingdong

AU - Zhu, Guangzhi

AU - Wang, Xiangkun

AU - Winkler, Cheryl Ann

AU - O’Brien, Stephen J.

AU - Peng, Tao

AU - O'Brien, Stephen James

PY - 2018/4/10

Y1 - 2018/4/10

N2 - Hepatocellular carcinoma (HCC) is the most frequent malignancy of the liver. Transforming growth factor beta 1 (TGFB1) and marker of proliferation Ki-67 (MKI67) regulate cell proliferation, differentiation, and growth. The association between MKI67 and TGFB1 expression and its clinical implications in HCC remain unknown. Methods: Public databases were used to analyze TGFB1 and MKI67 expression in different pathologic grades/stages and tissue types of HCC. The association between MKI67 and TGFB1 expression was explored using pathway analysis and in a HepG2 cell line treated with TGFB1. Survival analysis was performed to evaluate the prognostic value of TGFB1 and MKI67 expression in patients with hepatitis B virus (HBV)-related HCC. Results: We identified that MKI67 expression was upregulated in liver cancer tissues. MKI67 and TGFB1 expression levels were different in various stages and tissue types of liver cancer. Furthermore, MKI67 expression was associated with TGFB1 expression in liver cancer tissues and HepG2 cells. Patients with HBV-related HCC and a higher level of MKI67 expression had a worse prognosis. Moreover, a nomogram was conducted to predict the clinical outcomes of patients with HBV-related HCC. Conclusion: MKI67 expression level was associated with TGFB1 expression in liver cancer tissues and a HepG2 cell line. MKI67 expression level can predict the clinical outcomes of patients with HBV-related HCC.

AB - Hepatocellular carcinoma (HCC) is the most frequent malignancy of the liver. Transforming growth factor beta 1 (TGFB1) and marker of proliferation Ki-67 (MKI67) regulate cell proliferation, differentiation, and growth. The association between MKI67 and TGFB1 expression and its clinical implications in HCC remain unknown. Methods: Public databases were used to analyze TGFB1 and MKI67 expression in different pathologic grades/stages and tissue types of HCC. The association between MKI67 and TGFB1 expression was explored using pathway analysis and in a HepG2 cell line treated with TGFB1. Survival analysis was performed to evaluate the prognostic value of TGFB1 and MKI67 expression in patients with hepatitis B virus (HBV)-related HCC. Results: We identified that MKI67 expression was upregulated in liver cancer tissues. MKI67 and TGFB1 expression levels were different in various stages and tissue types of liver cancer. Furthermore, MKI67 expression was associated with TGFB1 expression in liver cancer tissues and HepG2 cells. Patients with HBV-related HCC and a higher level of MKI67 expression had a worse prognosis. Moreover, a nomogram was conducted to predict the clinical outcomes of patients with HBV-related HCC. Conclusion: MKI67 expression level was associated with TGFB1 expression in liver cancer tissues and a HepG2 cell line. MKI67 expression level can predict the clinical outcomes of patients with HBV-related HCC.

KW - HBV-related HCC

KW - MKI67

KW - Nomogram

KW - TGFB1

UR - https://nsuworks.nova.edu/cnso_bio_facarticles/1089

UR - https://www.scopus.com/pages/publications/85047112631

UR - https://www.scopus.com/pages/publications/85047112631#tab=citedBy

U2 - 10.2147/cmar.s162595

DO - 10.2147/cmar.s162595

M3 - Article

C2 - 29692627

SN - 1179-1322

VL - 10

SP - 679

EP - 696

JO - Cancer Management and Research

JF - Cancer Management and Research

ER -

Marker of proliferation Ki-67 expression is associated with transforming growth factor beta 1 and can predict the prognosis of patients with hepatic B virus-related hepatocellular carcinoma

Abstract

Bibliographical note

Funding

ASJC Scopus Subject Areas

Keywords

Disciplines

Access to Document

Other files and links

Fingerprint

Cite this